321 related articles for article (PubMed ID: 28655469)
21. Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells.
Belyakov IM; Hammond SA; Ahlers JD; Glenn GM; Berzofsky JA
J Clin Invest; 2004 Apr; 113(7):998-1007. PubMed ID: 15057306
[TBL] [Abstract][Full Text] [Related]
22. Biology of cloned cytotoxic T lymphocytes specific for lymphocytic choriomeningitis virus. VI. Migration and activity in vivo in acute and persistent infection.
Byrne JA; Oldstone MB
J Immunol; 1986 Jan; 136(2):698-704. PubMed ID: 2416821
[TBL] [Abstract][Full Text] [Related]
23. Adenovirus Serotype 5 Vaccination Results in Suboptimal CD4 T Helper 1 Responses in Mice.
Lee J; Hashimoto M; Im SJ; Araki K; Jin HT; Davis CW; Konieczny BT; Spies GA; McElrath MJ; Ahmed R
J Virol; 2017 Mar; 91(5):. PubMed ID: 28003483
[TBL] [Abstract][Full Text] [Related]
24. Mast cells are crucial for early inflammation, migration of Langerhans cells, and CTL responses following topical application of TLR7 ligand in mice.
Heib V; Becker M; Warger T; Rechtsteiner G; Tertilt C; Klein M; Bopp T; Taube C; Schild H; Schmitt E; Stassen M
Blood; 2007 Aug; 110(3):946-53. PubMed ID: 17446350
[TBL] [Abstract][Full Text] [Related]
25. Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod.
Rechtsteiner G; Warger T; Osterloh P; Schild H; Radsak MP
J Immunol; 2005 Mar; 174(5):2476-80. PubMed ID: 15728450
[TBL] [Abstract][Full Text] [Related]
26. Azithromycin impairs TLR7 signaling in dendritic cells and improves the severity of imiquimod-induced psoriasis-like skin inflammation in mice.
Huang SW; Chen YJ; Wang ST; Ho LW; Kao JK; Narita M; Takahashi M; Wu CY; Cheng HY; Shieh JJ
J Dermatol Sci; 2016 Oct; 84(1):59-70. PubMed ID: 27449383
[TBL] [Abstract][Full Text] [Related]
27. In vivo treatment with a MHC class I-restricted blocking peptide can prevent virus-induced autoimmune diabetes.
von Herrath MG; Coon B; Lewicki H; Mazarguil H; Gairin JE; Oldstone MB
J Immunol; 1998 Nov; 161(9):5087-96. PubMed ID: 9794447
[TBL] [Abstract][Full Text] [Related]
28. The virus-specific and allospecific cytotoxic T-lymphocyte response to lymphocytic choriomeningitis virus is modified in a subpopulation of CD8(+) T cells coexpressing the inhibitory major histocompatibility complex class I receptor Ly49G2.
Peacock CD; Lin MY; Ortaldo JR; Welsh RM
J Virol; 2000 Aug; 74(15):7032-8. PubMed ID: 10888642
[TBL] [Abstract][Full Text] [Related]
29. Imiquimod-induced TLR7 signaling enhances repair of DNA damage induced by ultraviolet light in bone marrow-derived cells.
Fishelevich R; Zhao Y; Tuchinda P; Liu H; Nakazono A; Tammaro A; Meng TC; Lee J; Gaspari AA
J Immunol; 2011 Aug; 187(4):1664-73. PubMed ID: 21765012
[TBL] [Abstract][Full Text] [Related]
30. Efficient control of chronic LCMV infection by a CD4 T cell epitope-based heterologous prime-boost vaccination in a murine model.
He R; Yang X; Liu C; Chen X; Wang L; Xiao M; Ye J; Wu Y; Ye L
Cell Mol Immunol; 2018 Sep; 15(9):815-826. PubMed ID: 28287115
[TBL] [Abstract][Full Text] [Related]
31. 4-1BB costimulation is required for protective anti-viral immunity after peptide vaccination.
Tan JT; Whitmire JK; Murali-Krishna K; Ahmed R; Altman JD; Mittler RS; Sette A; Pearson TC; Larsen CP
J Immunol; 2000 Mar; 164(5):2320-5. PubMed ID: 10679066
[TBL] [Abstract][Full Text] [Related]
32. Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod.
Wenzel J; Uerlich M; Haller O; Bieber T; Tueting T
J Cutan Pathol; 2005 Apr; 32(4):257-62. PubMed ID: 15769273
[TBL] [Abstract][Full Text] [Related]
33. Self-assembling peptide for co-delivery of HIV-1 CD8+ T cells epitope and Toll-like receptor 7/8 agonists R848 to induce maturation of monocyte derived dendritic cell and augment polyfunctional cytotoxic T lymphocyte (CTL) response.
Ding Y; Liu J; Lu S; Igweze J; Xu W; Kuang D; Zealey C; Liu D; Gregor A; Bozorgzad A; Zhang L; Yue E; Mujib S; Ostrowski M; Chen P
J Control Release; 2016 Aug; 236():22-30. PubMed ID: 27297778
[TBL] [Abstract][Full Text] [Related]
34. Topical imiquimod treatment prevents UV-light induced loss of contact hypersensitivity and immune tolerance.
Thatcher TH; Luzina I; Fishelevich R; Tomai MA; Miller RL; Gaspari AA
J Invest Dermatol; 2006 Apr; 126(4):821-31. PubMed ID: 16439962
[TBL] [Abstract][Full Text] [Related]
35. Topical rather than intradermal application of the TLR7 ligand imiquimod leads to human dermal dendritic cell maturation and CD8+ T-cell cross-priming.
Fehres CM; Bruijns SC; van Beelen AJ; Kalay H; Ambrosini M; Hooijberg E; Unger WW; de Gruijl TD; van Kooyk Y
Eur J Immunol; 2014 Aug; 44(8):2415-24. PubMed ID: 24825342
[TBL] [Abstract][Full Text] [Related]
36. A West Nile virus NS4B-P38G mutant strain induces adaptive immunity via TLR7-MyD88-dependent and independent signaling pathways.
Xie G; Welte T; Wang J; Whiteman MC; Wicker JA; Saxena V; Cong Y; Barrett AD; Wang T
Vaccine; 2013 Aug; 31(38):4143-51. PubMed ID: 23845800
[TBL] [Abstract][Full Text] [Related]
37. Vaccination and protection from a lethal viral infection: identification, incorporation, and use of a cytotoxic T lymphocyte glycoprotein epitope.
Klavinskis LS; Whitton JL; Joly E; Oldstone MB
Virology; 1990 Oct; 178(2):393-400. PubMed ID: 1699348
[TBL] [Abstract][Full Text] [Related]
38. Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells.
Drobits B; Holcmann M; Amberg N; Swiecki M; Grundtner R; Hammer M; Colonna M; Sibilia M
J Clin Invest; 2012 Feb; 122(2):575-85. PubMed ID: 22251703
[TBL] [Abstract][Full Text] [Related]
39. Virus-specific cytotoxic T cell-mediated lysis of lymphocytes in vitro and in vivo.
Kyburz D; Speiser DE; Aebischer T; Hengartner H; Zinkernagel RM
J Immunol; 1993 Jun; 150(11):5051-8. PubMed ID: 7684417
[TBL] [Abstract][Full Text] [Related]
40. Protective antiviral cytotoxic T cell memory is most efficiently maintained by restimulation via dendritic cells.
Ludewig B; Oehen S; Barchiesi F; Schwendener RA; Hengartner H; Zinkernagel RM
J Immunol; 1999 Aug; 163(4):1839-44. PubMed ID: 10438917
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
